{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:55Z","timestamp":1789014535749,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Real-world data on sufficient\/insufficient response, and predictors of insufficient response, to acute treatments for migraine are limited in Japan. This study aimed to identify factors associated with insufficient response to acute treatment of migraine by exploring significant differences between people with migraine who sufficiently\/insufficiently respond to prescribed acute treatment in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective analysis of 2014 Adelphi Migraine Disease Specific Programme cross-sectional survey data collected from physicians and their consulting adult patients with migraine in Japan. Insufficient responders to prescribed acute treatment were patients who achieved headache pain freedom within 2\u2009h of acute treatment in no more than three of their last five migraine attacks. Factors associated with insufficient response to prescribed acute migraine treatment were identified using backward logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 227\/538 (42.2%) patients were classified as insufficient responders to prescribed acute migraine treatment. Significantly more insufficient responders than sufficient responders had consulted a neurologist or a migraine\/headache specialist, and had chronic migraine or medication-overuse or tension-type headaches (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). More insufficient responders than sufficient responders reported taking acute treatment when\/after the pain started (77.0 vs. 68.9%) than at first sign of migraine (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Compared with sufficient responders, insufficient responders reported a significantly higher mean\u2009\u00b1\u2009standard deviation (SD) Migraine Disability Assessment total score (12.7\u2009\u00b1\u200923.3 vs. 5.8\u2009\u00b1\u200910.4,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and lower quality of life (EuroQol-5 Dimensions utility score 0.847\u2009\u00b1\u20090.19 vs. 0.883\u2009\u00b1\u20090.16,<jats:italic>p<\/jats:italic>\u2009=\u20090.024). Factors significantly associated with insufficient response to acute treatment included seeing a neurologist versus an internist (odds ratio [OR] 1.93; 95% confidence interval [CI] 1.29\u20132.88;<jats:italic>p<\/jats:italic>\u2009=\u20090.002), taking acute medication when\/after pain started versus at first sign of migraine (OR 1.65; 95% CI 1.05\u20132.60;<jats:italic>p<\/jats:italic>\u2009=\u20090.030), a higher MIDAS total score (OR 1.04; 95% CI 1.02\u20131.06;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and presence of comorbid cardiovascular disease (OR 0.53; 95% CI 0.28\u20130.98;<jats:italic>p<\/jats:italic>\u2009=\u20090.044).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Many people with migraine in Japan struggle to adequately treat migraine attacks with prescribed acute medication and exhibit high levels of unmet need for acute treatment. Optimized management strategies utilizing existing therapeutic options as well as additional effective therapeutic options for migraine are required to improve symptoms and quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-020-01848-4","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T07:02:54Z","timestamp":1594191774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme"],"prefix":"10.1186","volume":"20","author":[{"given":"Koichi","family":"Hirata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Treuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"1848_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jns.2016.11.071","volume":"372","author":"YW Woldeamanuel","year":"2017","unstructured":"Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307\u201315.","journal-title":"J Neurol Sci"},{"key":"1848_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211\u201359.","journal-title":"Lancet"},{"key":"1848_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"HC Diener","year":"2019","unstructured":"Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the international headache society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia. 2019;39:687\u2013710.","journal-title":"Cephalalgia."},{"key":"1848_CR4","volume-title":"Clinical practice guideline for chronic headache","author":"Japanese Society of Neurology and the Japanese Headache Society","year":"2013","unstructured":"Japanese Society of Neurology and the Japanese Headache Society. Clinical practice guideline for chronic headache 2013. http:\/\/www.jhsnet.org\/english\/guideline2013.pdf Accessed 10 Oct 2019."},{"key":"1848_CR5","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.12154","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Buse DC, Serrano D, Halland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53:1300\u201311.","journal-title":"Headache."},{"key":"1848_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/head.12941","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Munjal S, Buse DC, et al. Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2016;56:1635\u201348.","journal-title":"Headache."},{"key":"1848_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688\u201395.","journal-title":"Neurology."},{"key":"1848_CR8","doi-asserted-by":"crossref","unstructured":"Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi Migraine Disease Specific Programme. J Headache Pain. 2019;20(1):68.","DOI":"10.1186\/s10194-019-1012-1"},{"issue":"11","key":"1848_CR9","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes \u2013 a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1848_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107\u201314.","journal-title":"Cephalalgia."},{"issue":"6 Suppl 1","key":"1848_CR11","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20\u20138.","journal-title":"Neurology."},{"issue":"1","key":"1848_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372.","journal-title":"Health Policy"},{"issue":"5","key":"1848_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics."},{"issue":"Suppl 1","key":"1848_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","volume":"42","author":"RB Lipton","year":"2002","unstructured":"Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(Suppl 1):3\u20139.","journal-title":"Headache."},{"key":"1848_CR15","first-page":"1","volume":"38","author":"ICHD-3. Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"ICHD-3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211 https:\/\/www.ichd-3.org\/. Accessed 22 Nov 2018.","journal-title":"Cephalalgia"},{"key":"1848_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86\u201392.","journal-title":"Curr Pain Headache Rep"},{"key":"1848_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1848_CR18","doi-asserted-by":"crossref","unstructured":"Blumenfeld AK, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2010;31(3):301\u201315.","DOI":"10.1177\/0333102410381145"},{"key":"1848_CR19","doi-asserted-by":"publisher","unstructured":"Lombard L, Ye W, Nichols R, et al. A real-world analysis of patient characteristics, treatment patterns, and level of impairment in patients with migraine who are insufficient responders versus responders to acute treatment. Headache. 2020. https:\/\/doi.org\/10.1111\/head.13835.","DOI":"10.1111\/head.13835"},{"issue":"1","key":"1848_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W, et al. A global real-world assessment of the impact on the health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41.","journal-title":"J Headache Pain."},{"issue":"2","key":"1848_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1526-4610.2005.05031.x","volume":"45","author":"DW Dodick","year":"2005","unstructured":"Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache. 2005;45(2):156\u201362.","journal-title":"Headache."},{"key":"1848_CR22","unstructured":"Oliver RL, Taylor A. Treatment-resistant migraines. Pract Pain Manage. 2012;4 https:\/\/www.practicalpainmanagement.com\/pain\/headache\/migraine\/treatment-resistant-migraines. Accessed 10 Oct 2019."},{"key":"1848_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1177\/0333102409354390","volume":"30","author":"F Sheftell","year":"2010","unstructured":"Sheftell F, Almas M, Weeks R, et al. Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia. 2010;30:838\u201346.","journal-title":"Cephalalgia."},{"issue":"5","key":"1848_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/0333102413512035","volume":"34","author":"SH Landy","year":"2014","unstructured":"Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E. Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post-hoc analysis of four randomized trials of eletriptan 40 mg. Cephalalgia. 2014;34(5):376\u201381.","journal-title":"Cephalalgia."},{"issue":"4","key":"1848_CR25","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/head.12553","volume":"55","author":"D Serrano","year":"2015","unstructured":"Serrano D, Buse DC, Manack Adams A, et al. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2015;55(4):502\u201318. https:\/\/doi.org\/10.1111\/head.12553.","journal-title":"Headache."},{"key":"1848_CR26","doi-asserted-by":"publisher","unstructured":"Meyers JL, Davis KL, Lenz RA, et al. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019. https:\/\/doi.org\/10.1177\/0333102419851855.","DOI":"10.1177\/0333102419851855"},{"key":"1848_CR27","first-page":"271","volume":"83","author":"B Gilmore","year":"2011","unstructured":"Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011;83:271\u201380.","journal-title":"Am Fam Physician"},{"key":"1848_CR28","unstructured":"Imitrex (sumatriptan succinate) tablets, for oral use [prescribing information]. Research Triangle Park, NC, USA: GlaxoSmithKline; 2017. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Imitrex_Tablets\/pdf\/IMITREX-TABLETS-PI-PIL.PDF. Accessed 27 Apr 2020."},{"issue":"Suppl 4","key":"1848_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221\u201335.","journal-title":"Headache."},{"key":"1848_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1212\/01.WNL.0000133207.70312.30","volume":"63","author":"H Christoph-Diener","year":"2004","unstructured":"Christoph-Diener H, Ferrari M, Mansbach H, et al. Predicting the response to sumatriptan: the Sumatriptan Naratriptan aggregate patient database. Neurology. 2004;63:520\u20134.","journal-title":"Neurology."},{"key":"1848_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1526-4610.2007.00756.x","volume":"47","author":"FG Freitag","year":"2007","unstructured":"Freitag FG, Finlayson G, Rapoport AM, et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg time versus intensity migraine study (AIMS). Headache. 2007;47:519\u201330.","journal-title":"Headache."},{"key":"1848_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1468-2982.2007.01457.x","volume":"28","author":"HC Diener","year":"2008","unstructured":"Diener HC, Dodick DW, Goadsby PJ, et al. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia. 2008;28:35\u201340.","journal-title":"Cephalalgia."},{"key":"1848_CR33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1526-4610.2007.00868.x","volume":"48","author":"DW Dodick","year":"2008","unstructured":"Dodick DW, Lipton RB, Goadsby PJ, et al. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache. 2008;48:184\u201393.","journal-title":"Headache."},{"issue":"7","key":"1848_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/head.13115","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Munjal S, Buse DC, et al. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention study. Headache. 2017;57(7):1026\u201340.","journal-title":"Headache."},{"key":"1848_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s10194-019-0987-y","volume":"20","author":"TF Hansen","year":"2019","unstructured":"Hansen TF, Chalmer AM, Haspang TM, et al. Predicting response using pharmacy register in migraine. J Headache Pain. 2019;20:31.","journal-title":"J Headache Pain."},{"key":"1848_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11136-015-1108-2","volume":"25","author":"T Shiroiwa","year":"2016","unstructured":"Shiroiwa T, Fukuda T, Ikeda, et al. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016;25:707\u201319.","journal-title":"Qual Life Res"},{"key":"1848_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/0333102413480756","volume":"33","author":"M Viana","year":"2013","unstructured":"Viana M, Genazzani AA, Terrazzino S, et al. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33:891\u20136.","journal-title":"Cephalalgia."},{"key":"1848_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1526-4610.2010.01790.x","volume":"51","author":"TW Ho","year":"2011","unstructured":"Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient\u2019s historical triptan response. Headache. 2011;51:64\u201372.","journal-title":"Headache."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01848-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T14:02:39Z","timestamp":1723212159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01848-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01848-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Disease Specific Programme (DSP) data were collected in accordance with Adelphi Real World procedures, which are compliant with the Health Information Technology for Economic and Clinical Health (HITECH) Act and the Health Insurance Portability and Accountability Act (HIPAA). As a matter of routine, Adelphi Real World establishes a Master Services Agreement with each fieldwork partner. This includes the conditions that agencies have to follow local guidelines in addition to adhering to the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct and allows for circumstances where local regulations may be different to (more stringent than) EphMRA guidelines. As this was a retrospective analysis that used deidentified data that had been previously collected, patient participants were not required to provide formal Consent to Release Information forms for the current analyses; the original consent from those who provided data in the DSP covered the planned analyses in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KH reports grants from the Ministry of Health, Labor and Welfare, grants from The Japan Agency for Medical Research and Development, and non-financial support from Alexion Pharmaceuticals, Inc., during the conduct of the study. KU, WY, YK, MK, NR and TT are full-time employees and minor stock-holders of Eli Lilly and Company. SC and JJ are full-time employees of Adelphi Real World.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}